• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Thorax. Plasma 25-hydroxyvitamin D, lung function and risk of chronic obstructive pulmonary disease

Giuseppe

Emeritus
[Source: Thorax, full page: (LINK). Abstract, edited.]


<CITE><ABBR>Thorax</ABBR> doi:10.1136/thoraxjnl-2013-203682 </CITE>
<CITE></CITE>
<CITE></CITE>Chronic obstructive pulmonary disease / Original article

Plasma 25-hydroxyvitamin D, lung function and risk of chronic obstructive pulmonary disease


Shoaib Afzal 1,2, Peter Lange 2,3,4,5, Stig E Bojesen 1,2,3,6, Jacob J Freiberg 1,2, B?rge G Nordestgaard 1,2,3,6

Author Affiliations: <SUP>1</SUP>Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark <SUP>2</SUP>Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark <SUP>3</SUP>Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Frederiksberg, Denmark <SUP>4</SUP>Faculty of Health and Medical Sciences, Department of Public Health, Section of Social Medicine, University of Copenhagen, Copenhagen, Denmark <SUP>5</SUP>Section of Respiratory Medicine, Hvidovre Hospital, Copenhagen University Hospital, Hvidovre, Denmark <SUP>6</SUP>Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Correspondence to Professor B?rge G Nordestgaard, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark; Boerge.Nordestgaard@regionh.dk

Received 4 April 2013. Revised 13 June 2013. Accepted 8 July 2013. Published Online First 1 August 2013


Abstract

Background

25-hydroxyvitamin D (25(OH)D) may be associated with lung function through modulation of pulmonary protease-antiprotease imbalance, airway inflammation, lung remodelling and oxidative stress. We examined the association of plasma 25(OH)D levels with lung function, lung function decline and risk of chronic obstructive pulmonary disease (COPD).


Methods

Plasma 25(OH)D was measured in 10 116 participants in the Copenhagen City Heart Study and in 8391 participants in the Copenhagen General Population Study. In the former study, up to three measurements of lung function spanning 20 years allowed analyses of lung function decline.


Results

In both cohorts, forced vital capacity in % of predicted was 7% lower and forced expiratory volume in 1 s in % of predicted was 7?10% lower for lowest versus highest decile of 25(OH)D (p<SUB>trend</SUB>≤1?10<SUP>−28</SUP>). In prospective analyses, participants in the lower versus higher 25(OH)D quintiles had a faster decline in forced expiratory volume in 1 s % predicted (p<SUB>interaction</SUB>=1?10<SUP>−7</SUP>) and forced vital capacity % predicted (p<SUB>interaction</SUB>=8?10<SUP>−8</SUP>). In cross-sectional analyses, multivariable adjusted ORs for COPD were 2.30 (95% CI 1.55 to 3.41) and 3.06 (1.97 to 4.76) for lowest versus highest quintile in the Copenhagen City Heart Study using Global Initiative for Chronic Obstructive Lung Disease (GOLD) and lower limit of normal criteria. The corresponding ORs were 1.82 (1.13 to 2.92) and 2.23 (1.35 to 3.69) in the Copenhagen General Population Study. In prospective analyses, corresponding multivariable adjusted HRs for developing COPD were 1.58 (1.05 to 2.40) and 2.00 (1.19 to 3.36).


Conclusions

We observed a novel association of lower plasma 25(OH)D levels with faster decline in lung function and with a higher risk of COPD in prospective analyses.


-
------
 
Back
Top Bottom